Sugi Predict

Sugi Predict / Compounds / SCHEMBL507496

SCHEMBL507496

SCHEMBL507496

Cc1ccc2sc(-c3ccccc3)nc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 7/20 0.71
▸ MAPT P10636 6/20 0.71
▸ TP53 P04637 1/20 0.71
▸ NPC1 O15118 8/20 0.58
▸ RAB9A P51151 8/20 0.58
▸ NFKB1 P19838 6/20 0.58
▸ NFKB2 Q00653 6/20 0.58
▸ RELA Q04206 6/20 0.58
▸ HPGD P15428 4/20 0.58
▸ STAT1 P42224 1/20 0.58
▸ KDM4E B2RXH2 9/20 0.57
▸ ALDH1A1 P00352 5/20 0.56
▸ GAA P10253 4/20 0.56
▸ GLA P06280 3/20 0.56
▸ PKM P14618 3/20 0.56
▸ L3MBTL1 Q9Y468 2/20 0.56
▸ APP P05067 5/20 0.54
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12408909 0.91 MAPT (0.84) SMN1; SMN2MAPTTP53NPC1RAB9A
SCHEMBL14878460 0.89 MAPT (0.81) SMN1; SMN2MAPTTP53NPC1RAB9A
SCHEMBL13645821 0.87 SMN1; SMN2 (0.60) SMN1; SMN2MAPTTP53NPC1RAB9A
SCHEMBL507097 0.86 MAPT (0.71) SMN1; SMN2MAPTTP53NPC1RAB9A
SCHEMBL23954319 0.86 APP (0.58) SMN1; SMN2MAPTTP53NPC1RAB9A
SCHEMBL12408938 0.84 SMN1; SMN2 (0.57) SMN1; SMN2MAPTTP53NPC1RAB9A
SCHEMBL8534189 0.83 MAPT (1.00) SMN1; SMN2MAPTTP53NPC1RAB9A
SCHEMBL19174390 0.83 SMN1; SMN2 (0.58) SMN1; SMN2MAPTTP53NPC1RAB9A
SCHEMBL6255382 0.82 SMN1; SMN2 (0.51) SMN1; SMN2MAPTTP53NPC1RAB9A
SCHEMBL27045588 0.82 MAPT (0.70) SMN1; SMN2MAPTTP53NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230172057-A1 HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) 2023-06-01 — — US disclosed
US-20210095196-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2021-04-01 — — US disclosed
CN-109180590-A A method of Benzoheterocyclic compounds are quickly prepared using physical grinding method under room temperature solvent-free 福建医科大学 2019-01-11 — — CN disclosed
CN-106488762-A Sunscreen with visual shading of excessive whiteness due to titanium dioxide and zinc oxide upon skin application 株式会社资生堂 2017-03-08 — — CN disclosed
CN-106456469-A Cosmetic 堺化学工业株式会社 2017-02-22 — — CN disclosed
CN-106413677-A Anti-aging external skin preparation 株式会社林原 2017-02-15 — — CN disclosed
CN-106137862-A Composition containing nano Chinese angelica and cosmetics 南京谷润生物科技有限公司 2016-11-23 — — CN disclosed
CN-102892399-B Composition for external application to skin, cosmetic and cleansing agent 日清奥利友集团株式会社 2016-11-09 — — CN disclosed
CN-105960379-A Hexagonal plate-like zinc oxide particles, method for producing same, cosmetic, filler, resin composition, infrared-reflective material, and coating composition 堺化学工业株式会社 2016-09-21 — — CN disclosed
CN-105851057-A SURFACE TREATED ZINC OXIDE POWDER, ANTIBACTERIAL AGENT, AND ANTIBACTERIAL COMPOSITION 堺化学工业株式会社 2016-08-17 — — CN disclosed
CN-102036686-A Water-containing composition SHISEIDO CO LTD 2011-04-27 — — CN disclosed
CN-1784215-B Melanogenesis promoter and melanogenesis promoter composition SAKAMOTO BIO CO LTD 2010-10-06 — — CN disclosed
CN-100574740-C The water in oil emulsion liquid formulation of external preparation for skin NISSHIN OILLIO LTD 2009-12-30 — — CN disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 — — US disclosed
CN-1968690-A Inflammation inhibitor containing zinc salt of acylamino acid AJINOMOTO KK (JP) 2007-05-23 — — CN disclosed
CN-1934088-A As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * LILLY CO ELI (US) 2007-03-21 — — CN disclosed
EP-1720836-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2006-11-15 — — EP disclosed
CN-1784215-A Melanogenesis promoter and melanogenesis promoter composition SAKAMOTO BIO CO LTD (JP) 2006-06-07 — — CN disclosed
WO-2005082859-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2005-09-09 — — WO disclosed
CN-1615118-A Water-in-oil emulsion preparation for external use on skin NISSHIN OILLIO LTD (JP) 2005-05-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 SMN1; SMN2 1853/4885MAPT 4341/4885TP53 4836/4885
US-20230172057-A1 HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE CHRM1, CHRM2, CHRM4 SMN1; SMN2 3262/4885MAPT 4606/4885TP53 4292/4885
US-20210095196-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES SSB, RO60, OSBP SMN1; SMN2 4645/4885MAPT 2600/4885TP53 1150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.